Bayer Bayer Malaysia’s managing director, Thomas Steffen, discusses the key differences and opportunities offered by the Malaysian market and calls for more information to help the promotion of oral contraception in order to strengthen women’s role in society. As you are managing the pharmaceutical business in both Malaysia and Singapore, how…
UAE How quickly can a country truly transform its healthcare system, while making it sustainable for the future? The mindset of Emiratis is that anything that is feasible and beneficial for the country should and will be done, regardless of the cost. This is why health authorities have been moving at…
R&D Nelson Ambrogio, managing director of Bayer Portugal, talks about tthe collaboration between the industry and the government, he recent successes of his affiliate, and strategies for continued growth during the toughest years of the crisis in Portgugal. Why did you choose to come to Portugal during such a challenging time…
UAE Bassam Abdallah, Country Division Head of Bayer Healthcare, speaks about the UAE’s economic diversification evolution, how healthcare is the leading segment in this process, and what Bayer’s strategy is to keep up with the regions changing disease portfolio. In many ways the UAE is becoming a model for other countries…
Bayer Austria GmbH You have been with Bayer for almost 15 years. What would you say defines your loyalty to the company, and has the time so far met your original expectations? Bayer is a great company today; it was also a great company when I joined in 1998. The fascination with innovation…
Bayer Ireland Mr. Zimmermann, you came to manage the Irish affiliate of Bayer in 2010, after heading Business Management for Bayer Pharma Headquarters in Berlin. After these two years, what are your impressions of the state and nuances of the Irish market, and what would you say surprised you most about the…
Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…
Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…
Array Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s main ambitions in China over the next five years. It has been a rollercoaster four years…
Bayer Australia Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines in the industry. In Australia, the company is launching in the next three years, 18 new products or product line…
Bayer Thailand Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank Thailand as 12th among emerging countries in pharma and anticipate Thailand becoming the eighth largest economy and market by 2016.…
Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…
See our Cookie Privacy Policy Here
